Johannes Oldenburg, MD (he/him/his)

Professor, Chairman and Director
University Clinic Bonn AöR, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany
Bonn, Nordrhein-Westfalen, Germany

Professor Oldenburg is a Director at the Institute of Experimental Haematology and Transfusion Medicine and at the Haemophilia Centre at the University Clinic in Bonn, Germany. His research interests include the molecular genetics of blood coagulation factors, specifically with haemophilia and vitamin K pathways with more than 500 peer reviewed publications in these fields. He is the recipient of the GTH Alexander Schmidt Award (2000) and the ISTH Biennial Investigator Recognition Award (2007). He served as President of the 26th ISTH Congress in 2017, and from 2019-2023 he has been President of the GTH.

Presentation(s):

• OC 04.2 - B-Domain deleted Factor VIII shows clear differences in intracellular processing and cellular responses when compared to full length Factor VIII

  Saturday, June 24, 2023
  13:15 – 13:30 ET

• OC 04.3 - Prospective FVIII intracellular trafficking routes involving GABARAP

  Saturday, June 24, 2023
  13:30 – 13:45 ET

• OC 07.2 - Investigating the dominant negative effect of heterozygous F13B gene mutations detected from mild FXIII deficiency patients

  Saturday, June 24, 2023
  13:15 – 13:30 ET

• LB 01.2 - Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA)

  Sunday, June 25, 2023
  11:00 – 11:15 ET

• OC 20.1 - Bleeding, FVIII activity, and safety 3 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

  Sunday, June 25, 2023
  14:45 – 15:00 ET

• PB0143 - Induced B cell tolerance in Hemophilia A mice is destroyed by infections

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0151 - The Effect of Single and Combined Knockouts of GABARAPs proteins family on FVIII Intracellular Localization and Secretion

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0158 - Preanalytical Quenching of FVIII Using FVIII-Inhibitors Improves the Specificity of Functional Emicizumab Testing

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0217 - Genotypic distribution in congenital rare bleeding disorders patients of Asian Indian origin: Results of a collaborative ISTH-RTC study

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• OC 33.3 - Evaluating the impact of anti-PEG antibodies on activation of PEGylated therapeutic FVIII products

  Monday, June 26, 2023
  11:15 – 11:30 ET

• OC 33.5 - Structural characterization of coagulation factor VIII

  Monday, June 26, 2023
  11:45 – 12:00 ET

• OC 43.4 - Effectiveness of emicizumab under real-world conditions in patients of all ages with hemophilia A with and without FVIII inhibitors: interim analysis of the non-interventional study EMIIL

  Monday, June 26, 2023
  15:30 – 15:45 ET

• PB0624 - A-SURE: Intra-patient Comparison of Prophylactic Effectiveness of a Recombinant Factor VIII Fc Fusion Protein Versus Standard Half-life Factor VIII in Hemophilia A

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0681 - German experience with simoctocog alfa during surgery in female haemophilia A carriers

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0830 - Inspecting underlying pathogenesis mechanisms of von Willebrand disease variants sited in A domains of the von Willebrand factor

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB1073 - Endothelial Cell-Dependent Activated Protein C Formation is Significantly Decreased in Hereditary Protein C Deficiency Regardless of Underlying Gene Variant and Residual Activity in Plasma

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1075 - APC Response Rates in Factor V Leiden Carriers Correlate with Thrombotic Risk Independent from Endothelial Properties: Results from an Endothelial Cell-based Ex Vivo Model of the Protein C Pathway

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1198 - Retrospective Genotypic Data Analysis of Patients with Suspected Hereditary Fibrinogen Deficiency

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1249 - Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents With Severe Hemophilia A

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1255 - An update on real-world use of rVIII-SingleChain in patients with haemophilia A in Germany: Interim results from a prospective, non-interventional study

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1263 - Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1292 - Rationale and Design of pathfinderReal: A Prospective, Non-Interventional Study Assessing Joint Health in Adults With Haemophilia A After Switching to Prophylaxis With Turoctocog Alpha Pegol (N8-GP)

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1296 - A prospective, non-interventional study to investigate the effectiveness of rVIII-SingleChain in patients with hemophilia A

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1502 - Hemostatic imbalance associated with tamoxifen in estrogen receptor-positive breast cancer patients: an observational study

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PO10 - Nuwiq Dosing and outcomes In the ManagEment of women/girls with haemophilia A Needing FVIII treatment for Surgery – an International, Open-label, Non-controlled study (NuDIMENSION)

  Wednesday, June 28, 2023
  13:00 – 14:00 ET

• PO19 - Clinical experiences in managing the transition to rIX-FP: switching, surgical management and on-demand

  Wednesday, June 28, 2023
  13:00 – 14:00 ET